<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunotoxins (ITs) may be very potent to erradicate <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the influence of the IT-dose, in relation to the establishment of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>, on the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity of CD22-recombinant (rec) ricin A for a disseminated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> (Ramos) in <z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, the enhancement of the IT cytotoxicity in vivo by <z:chebi fb="3" ids="3638">chloroquine</z:chebi> was assessed </plain></SENT>
<SENT sid="3" pm="."><plain>CD22-rec ricin A appeared to be highly effective </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0003470'>Paralysis</z:hpo> of the hind legs was significantly delayed by a very low IT-dose of 2 microg administered intravenously (i.v.) 7 days after i.v. inoculation of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>Even a dose of 30 microg administered 21 days after inoculation of the target cells significantly delayed the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0003470'>paralysis</z:hpo> up to 8 days compared with the median <z:hpo ids='HP_0003470'>paralysis</z:hpo> time (MPT) of the control group </plain></SENT>
<SENT sid="6" pm="."><plain>The efficacy of treatment was obviously influenced by the establishment of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> load and localisation </plain></SENT>
<SENT sid="7" pm="."><plain>The anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity of 10 and 30 microg IT diminished when the IT was administered after increasing the time lag following inoculation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>Delaying IT administration resulted in growth of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>This implies that cells migrate to sanctuaries protected from the IT indicating that the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity was influenced by the accessibility of the IT to the target cells </plain></SENT>
<SENT sid="10" pm="."><plain>The in vivo anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity of CD22-rec ricin A could not be enhanced by simultaneously administered <z:chebi fb="3" ids="3638">chloroquine</z:chebi>, despite the continuous infusion with an intraperitoneally (i.p.) implanted mini-osmotic pump </plain></SENT>
<SENT sid="11" pm="."><plain>Ex vivo experiments revealed that the maximally tolerated serum concentration (3.9 microM) was too low to be effective </plain></SENT>
<SENT sid="12" pm="."><plain>In conclusion, CD22-rec ricin A is highly effective for in vivo treatment of B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, in particular if treatment is started when the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> load is low and before migration takes place to poorly accessible sanctuaries </plain></SENT>
</text></document>